Guiyu Zhao
Adult Health · Brooklyn, NYNPI 1821481896
Payments from drug & device makers
Across 134 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$876
- GSK$506
- Eisai Inc.$389
- AstraZeneca$369
- Bayer$237
- Boehringer Ingelheim$148
- plus $975 from 15 others
What the payments were for
- Food & beverage$3,499100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 35 | $876 |
| GSK | 17 | $506 |
| Eisai Inc. | 17 | $389 |
| AstraZeneca | 15 | $369 |
| Bayer | 9 | $237 |
| Boehringer Ingelheim | 2 | $148 |
| Genmab U.S., Inc. | 6 | $147 |
| Madrigal Pharmaceuticals | 1 | $137 |
| Lilly USA, LLC | 5 | $111 |
| Sumitomo Pharma America, Inc. | 4 | $102 |
| Esperion Therapeutics, Inc. | 5 | $99 |
| AbbVie | 4 | $87 |
| IBSA Pharma Inc. | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Pfizer | 2 | $46 |
| Baxter Healthcare | 1 | $39 |
| Caris MPI, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Immunogen, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,499 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 170 | $62,834 |
| JardianceEmpagliflozin | 59 | $36,137 |
| VemlidyTenofovir Alafenamide | 25 | $34,950 |
| Diclofenac Epolamine | 32 | $21,423 |
| ProliaDenosumab | 11 | $18,399 |
| EliquisApixaban | 16 | $12,479 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $11,078 |
| JanuviaSitagliptin Phosphate | 15 | $8,616 |
| Diclofenac Sodium | 27 | $6,996 |
| Tenofovir Disoproxil Fumarate | 24 | $3,113 |
| Estradiol | 32 | $2,737 |
| Clobetasol Propionate | 35 | $2,272 |
| Icosapent Ethyl | 15 | $2,039 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,948 |
| Mometasone Furoate | 26 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $148 | $36,13759 claims |
| MerckJanumet, Januvia | $876 | $19,69432 claims |
| PfizerEliquis | $46 | $12,47916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.
Other adult health in Brooklyn
- Huiwen YingBrooklyn$17K
- Joyce YeungBrooklyn$15K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.